Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
Vemurafenib is a potent inhibitor of BRAFV600E, C-Raf and wild type B-Raf (IC50 values are 13-31 nM, 6.7-48 nM and 100-160 nM, respectively. Vemurafenib also inhibits SRMS, ACK1 KHS1, FGR (IC50 values are 18 nM, 19 nM, 51 nM and 63 nM, respectively). Vemurafenib shows antitumor activity and induces autophagy in BRAF-mutant thyroid cancer cells.
Vemurafenib is also offered as part of the Tocriscreen Kinase Inhibitor Library. Find out more about compound libraries available from Tocris.
|Storage||Store at -20°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
The following data is based on the product molecular weight 489.92. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||2.04 mL||10.21 mL||20.41 mL|
|5 mM||0.41 mL||2.04 mL||4.08 mL|
|10 mM||0.2 mL||1.02 mL||2.04 mL|
|50 mM||0.04 mL||0.2 mL||0.41 mL|
References are publications that support the biological activity of the product.
Wang et al (2017) Targeting autophagy sensitizes BRAF-mutant thyroid cancer to vemurafenib. J.Clin.Endocrinol.Metab. 102 634 PMID: 27754804
Ibrahim et al (2013) Chapter twenty-six - case history: vemurafenib, a potent, selective, and first-in-class inhibitor of mutant BRAF for the treatment of metastatic melanoma. Annu.Rep.Med.Chem. 48 435
Davis and Schlessinger (2012) The genesis of zelboraf: targeting mutant B-Raf in melanoma. J.Cell.Biol. 199 15 PMID: 23027900
If you know of a relevant reference for Vemurafenib, please let us know.
Keywords: Vemurafenib, Vemurafenib supplier, BRAF, kinases, inhibitors, inhibits, potent, BRAFV600E, CRAF, B-raf, c-raf, autophagy, antitumor, Raf, Kinase, 7309, Tocris Bioscience
Citations are publications that use Tocris products.
Currently there are no citations for Vemurafenib. Do you know of a great paper that uses Vemurafenib from Tocris? Please let us know.
There are currently no reviews for this product. Be the first to review Vemurafenib and earn rewards!
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.